-
PROVIDERS
Watch now
Are you getting the full picture? A webinar series on the power of comprehensive intelligent diagnostics
-
LIFE SCIENCES
ENROLL NOW
Tempus’ Patient-Derived Organoid ScreensEvaluate the efficacy of your preclinical compounds using fixed organoid panels designed for diverse therapeutic applications.Space is limited — enroll by June 30, 2025, to secure your spot.
-
PATIENTS
It's About Time
View the Tempus vision.
- RESOURCES
-
ABOUT US
View Job Postings
We’re looking for people who can change the world.
- INVESTORS
PROVIDERS /// ONCOLOGY
Creating more options for your patients
Our collection of offerings uncover unique insights that empower you to customize treatment for individual patients, throughout their cancer journey.
A comprehensive solution for all of your precision oncology needs
A comprehensive solution for all of your precision oncology needs
-
GENOMIC PROFILING
We deliver a comprehensive view of your patients through our tissue and liquid tests, DNA and RNA sequencing, somatic and germline tests, tumor-normal matched profiling, and MRD and monitoring test options.
-
ALGORITHMIC TESTS
We leverage our growing database to create specialized algorithms like Homologous Recombination Deficiency (HRD), Tumor Origin (TO), and DPYD, with more algorithms in development.
-
TEMPUS HUB
We offer a fast, reliable platform for ordering Tempus tests, accessing patient insights, and utilizing our AI-driven technologies seamlessly.
-
TEMPUS ONE
The first generative AI-enabled clinical assistant that provides access to patient insights directly at your fingertips.
-
EHR INTEGRATION
We offer easy access to current treatment options and relevant insights through our integration and connectivity capabilities.
-
TEMPUS+
We provide select participating institutions with access to technical support, customized to meet the unique needs and goals of your cancer center.
-
CLINICAL TRIAL MATCHING
We bring just-in-time clinical trial options to patients based on clinical and molecular data, for enrollment at your institution, through our TIME Trial Program—in days instead of months.
-
DIGITAL PATHOLOGY
We are developing AI capabilities to help pathologists find actionable markers in specimens to identify potential patients for clinical trials or precision therapeutics.
-
CARE PATHWAY SOLUTIONS
We empower physicians to deliver the next step in a patient’s care journey with our AI-enabled care pathway intelligence platform.
Streamlining your workflow
One order. One platform. One financial assistance program.
Browse our FAQsFinancial Assistance
Tempus is committed to providing easy and affordable access to our tests and services.
-
Apply for financial assistance online at access.tempus.com.
-
If approved, you will know immediately about the maximum out of pocket cost of your testing.
-
Please contact billing@tempus.com if you are concerned about out-of-pocket costs and would like to discuss your options.
All U.S.-based patients are eligible to apply for financial assistance regardless of insurance status. For uninsured and international patients, we offer a self-pay option. If you have any questions, please email patients@tempus.com.
Authorization for Medical Records: Through access.tempus.com, you will be directed to our Notice and Authorization for Medical Records authorization form. This optional form allows us to request outcomes and other medical records from your health care providers. Please see the form for more information.
We have established relationships that span from community practices to more than 50% of all academic medical centers in the United States.
-
6.5K+
oncologists rely on Tempus as their precision medicine partner
-
30K+
patients have been identified for potential enrollment into clinical trials in our network
-
8M+
de-identified research records
-
40+
operational countries across North, Central and South America, Europe, the Middle East, and Asia
-
UPCOMING WEBINAR:
Detection of KMT2A Partial Tandem Duplication (PTD) in AML by Whole Genome Sequencing (WGS): Addressing Limitations of Traditional Techniques in the Era of Revumenib Approval
In this study, we found that WGS is an effective tool for detecting KMT2A alterations that may be missed by traditional techniques such as NGS targeted capture, FISH or cytogenetics.
Read more -
UPCOMING WEBINAR:
Circulating Tumor DNA (ctDNA) Dynamics in Liver-Limited Metastatic Colorectal Cancer (mCRC) Patients Resected After Fi Rst-Linesystemic Treatment
xM demonstrates remarkable performance in predicting clinical recurrence and correlation to RFS at TPoS in LLD mCRC patients resected after upfront systemic therapy.
Read more -
UPCOMING WEBINAR:
A Molecular Biomarker for Early and Longitudinal Treatment Response Monitoring in a Real-World Cohort of Advanced Solid Tumors Treated With Targeted Therapies
The data in this study demonstrates that a molecular biomarker for targeted therapy treatment response monitoring both early on-treatment and in pts continually monitored may be a useful tool for treatment decision making.
Read more -
UPCOMING WEBINAR:
A Technology-Enabled Clinical Trial Program’s Impact on Patient Screening and Trial Enrollment in 2024
The Tempus AI TIME program facilitated the screening of 1.28M+ patients for over 95 clinical trials, averaging 1.57 consents per day over 1 year. Future trial matching strategies should utilize algorithmic screening and rapid activation processes to improve patient access and trial success.
Read more -
UPCOMING WEBINAR:
Analytical Validation of Next-Generation Sequencing-Based Comprehensive Liquid Biopsy Assay for Therapy Selection
Liquid biopsies are an increasingly important tool for the real-time monitoring of biomarkers, cancer recurrence, and disease burden in oncology practice. Tempus xF+ is a liquid biopsy assay that detects cell-free DNA in blood samples of patients with advanced solid tumors.
Read more -
UPCOMING WEBINAR:
Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality
gATM-associated cancers seem to require intact p53 activity and this synthetic essentiality may be used to guide targeted therapies that perturb canonical TP53 function.
Read more
Featured News and Events
view all news-
UPCOMING WEBINAR:
Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
Tempus announced a collaboration to develop a companion diagnostic (CDx) test with Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers.
Read more -
UPCOMING WEBINAR:
Tempus Enters Multi-Year Strategic Collaboration with Boehringer Ingelheim to Advance its Cancer Pipeline
Tempus announced a new strategic collaboration to advance Boehringer Ingelheim’s growing cancer pipeline. The new, multi-year collaboration builds on foundational work the two companies have conducted in the last few years, leveraging data and AI to further advance therapeutic research and development.
Read more -
UPCOMING WEBINAR:
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection
Tempus announced publication of its study, “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics
Read more -
UPCOMING WEBINAR:
Tempus Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
Tempus announced a multi-year, strategic collaborations with AstraZeneca (LSE/STO/Nasdaq: AZN) and Pathos AI, Inc., in which the companies will work together to build a multimodal foundation model in oncology which can be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community.
Read more -
UPCOMING WEBINAR:
Tempus Unveils Advisory Board Featuring Leading Physicians From Across the U.S.
Tempus announced the launch of the Tempus Advisory Board which is a vital resource in maintaining high standards and ensuring that the strategy and offerings continue to be grounded in expert knowledge from outside the organization.
Read more -
UPCOMING WEBINAR:
Tempus Announces Acquisition of Deep 6 AI
Tempus announced it has acquired Deep 6 AI, a leading AI-powered precision research platform for healthcare organizations and life sciences companies.
Read more
Validations and Resources
view all resources-
UPCOMING WEBINAR:
Tempus xT Validation
Our Tempus xT assay is designed to detect actionable oncologic targets by sequencing tumor samples with matched normal saliva or blood samples, when available.
Read more -
UPCOMING WEBINAR:
Tempus xF Validation
Our non-invasive Tempus xF liquid biopsy assay detects cell-free DNA (cfDNA) in blood specimens of advanced solid tumor patients.
Read more -
UPCOMING WEBINAR:
Standard Requisition Form
We offer an easy ordering process which allows you to order any of somatic and germline panels along with our add-on tests like HRD, TO and DPYD.
View here
-
Flora
“Having Tempus in my fight for cancer… it’s incredible.”
-
Bobbie
“I already know–thanks to [Tempus] testing–my first, second, and third lines of defense.”
-
Defne
“Without Tempus I couldn’t have reached any solution. It’s a new hope in life, for cancer.”
Partnering with Tempus is investing in the future
Every new test and data point strengthens our algorithms, predictions, and recommendations to improve treatment options for future patients.